HIM
CCXI

Hillsdale Investment Management’s ChemoCentryx, Inc. CCXI Stock Holding History

Hillsdale Investment Management’s Portfolio CCXI Stock Details CCXI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-14,600
Closed -$800K – 679
2020
Q3 		$800K Buy
14,600
+1,900
+15% +$102K 0.08% 241
2020
Q2 		$731K Buy
+12,700
New +$691K 0.07% 256
2013
Q4 		– Sell
-5,800
Closed -$32K – 600
2013
Q3 		$32K Buy
+5,800
New +$62.7K 0.01% 436

Other funds holding CCXI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Hillsdale Investment Management's CCXI Position: Q4 2020 in Review

Hillsdale Investment Management sold out of ChemoCentryx, Inc. (CCXI) in Q4 2020, closing a stake of 14,600 shares — an estimated $800K sold.

Hillsdale Investment Management first reported a position in CCXI in Q3 2013 and held it in 3 quarters. The position peaked at $800K in Q3 2020. 196 funds tracked by Wall St. Rank hold CCXI as of Q4 2020.

  • Hillsdale Investment Management reported no remaining ChemoCentryx, Inc. position as of Q4 2020 after selling out during the quarter.
  • Hillsdale Investment Management sold 14,600 ChemoCentryx, Inc. shares in Q4 2020, an estimated $800K.
  • Hillsdale Investment Management first reported a position in ChemoCentryx, Inc. in Q3 2013 and held it in 3 quarters.
  • Hillsdale Investment Management's ChemoCentryx, Inc. position peaked at $800K in Q3 2020.
  • 196 funds tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q4 2020.

Based on Hillsdale Investment Management's 13F filing for Q4 2020, filed 9 Feb 2021.